---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-041082"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:14:30.362269+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M

## Summary
- Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.
- BeOne retains share of royalty on annual ex-China net sales above $1.5B and all other Amgen collaboration rights.
- IMDELLTRA is a DLL3-targeting bispecific T-cell engager approved in US for ES-SCLC after platinum chemo.
- Transaction expected to close shortly; proceeds provide operational and strategic flexibility.

## SEC filing metadata
- accession: 0001628280-25-041082
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/0001628280-25-041082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/bgne-20250825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-041082
- JSON: https://secwatch.observer/filing/0001628280-25-041082.json
- Plain text: https://secwatch.observer/filing/0001628280-25-041082.txt

## Key facts
- Debt Financings
  BeOne Medicines Ltd. incurred debt of $885 million upfront payment, with option for up to $65 million additional with Royalty Pharma Investments 2023 ICAV maturing sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli.
  - Principal: $885 million upfront payment, with option for up to $65 million additional
  - Counterparty: Royalty Pharma Investments 2023 ICAV
  - Maturity: sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli
  - Event: incurrence
  source text: (the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000162828025041082/0001628280-25-041082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.